Information Provided By:
Fly News Breaks for September 18, 2017
NEOS
Sep 18, 2017 | 08:58 EDT
JMP Securities analyst Jason Butler said Neos Therapeutics' approval of Adzenys ER Oral Solution further builds out the company's ADHD portfolio, giving it the most complete offering of alternative dose forms of the most widely prescribed drugs used to treat the condition. He keeps an Outperform rating and $30 price target on Neos shares.
News For NEOS From the Last 2 Days
There are no results for your query NEOS
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.